Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: J Hepatol. 2015 Nov 7;64(3):699–707. doi: 10.1016/j.jhep.2015.11.002

Fig. 1. Hepatic Bid suppression in mice via siRNA.

Fig. 1

Optimization of the siRNA delivery system in wild type mice (A-C) and Bid suppression in NASH mice (D-G). (A) Relative expression of liver Bid mRNA after 2 days with 4 mg/kg Bid siRNA (10 different target sequences, no.1-10) -Invivofectamine2.0 complex. **P<0.01, ***P<0.001. (B) Relative expression of liver Bid mRNA after 14 days with 7 mg/kg Bid siRNA (no.3, 4, or 10) -Invivofectamine2.0 complex. **P<0.01, ***P<0.001. (C) Relative expression of liver Bid mRNA 2 days with 1.5 mg/kg Bid siRNA (no.3) -Invivofectamine3.0 complex. (D) Experimental design. (E) Relative expression of liver Bid mRNA at termination of treatment (22 wks) with control, Neg siRNA, or Bid siRNA. **P<0.01, ***P<0.001. (F) Protein expression of BID in whole liver by immunoblotting from mice fed a CDAA diet administered with control, Neg siRNA, or Bid siRNA. (G) Bar graph shows quantification of BID protein expression from immunoblotting. ***P<0.001. Values are mean ± SEM. Ctrl: Control, Neg siRNA: negative siRNA